2013
Adverse Events in an Integrated Home-Based Treatment Program for MDR-TB and HIV in KwaZulu-Natal, South Africa
Brust JC, Shah NS, van der Merwe TL, Bamber S, Ning Y, Heo M, Moll AP, Loveday M, Lalloo UG, Friedland GH, Gandhi NR. Adverse Events in an Integrated Home-Based Treatment Program for MDR-TB and HIV in KwaZulu-Natal, South Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2013, 62: 436-440. PMID: 23254152, PMCID: PMC3641171, DOI: 10.1097/qai.0b013e31828175ed.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisAdverse eventsAntiretroviral therapyCommon severe adverse eventsMDR-TB/HIVTreatment programConcurrent antiretroviral therapyMDR-TB patientsMDR-TB therapySevere adverse eventsHome-based treatment programHome-based care settingsRural KwaZulu-NatalMost patientsTherapy modificationConcurrent treatmentCare settingsHIVPatientsTherapyKwaZulu-NatalIntegrated HomeTolerabilityHypothyroidismTuberculosis
2009
A phase I study investigating the combination of orally bioavailable platinum and nanoparticle albumin-bound paclitaxel in advanced solid tumors
Deshpande H, Gettinger S, Rowen E, Abu-Khalaf M, Clarke J, Burns A, Kelly W. A phase I study investigating the combination of orally bioavailable platinum and nanoparticle albumin-bound paclitaxel in advanced solid tumors. Journal Of Clinical Oncology 2009, 27: e13501-e13501. DOI: 10.1200/jco.2009.27.15_suppl.e13501.Peer-Reviewed Original ResearchNanoparticle albumin-bound paclitaxelAlbumin-bound paclitaxelCohort 2Cohort 3Cohort 1Platinum agentsSolid tumorsDay 14Common severe adverse eventsGrade 3 anemiaMedian age 51Grade 4 neutropeniaStandard chemotherapy regimenAdvanced solid tumorsPhase 2 studySevere adverse eventsNeurological side effectsCycle 1Stable diseaseChemotherapy regimenDay 1 treatmentAdvanced malignanciesAdverse eventsPartial responseProgressive disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply